Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ATXS Astria Therapeutics Inc

8.910
-0.330-3.57%
Close 09/29 16:00 ET
8.9100.0000.00%
Post Mkt Price 09/29 16:00 ET
High
9.275
Open
9.140
Turnover
322.11K
Low
8.750
Pre Close
9.240
Volume
36.18K
Market Cap
135.24M
P/E(TTM)
Loss
52wk High
10.700
Shares
15.18M
P/E(Static)
Loss
52wk Low
2.360
Float Cap
75.51M
Bid/Ask %
33.33%
Historical High
1017.600
Shs Float
8.48M
Volume Ratio
0.58
Historical Low
2.360
Dividend TTM
--
Div Yield TTM
--
P/B
44.77
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.43%
Amplitude
5.68%
Avg Price
8.904
Lot Size
1
Float Cap
75.51M
Bid/Ask %
33.33%
Historical High
1017.600
Shs Float
8.48M
Volume Ratio
0.58
Historical Low
2.360
Dividend TTM
--
P/B
44.77
Dividend LFY
--
Turnover Ratio
0.43%
Amplitude
5.68%
Avg Price
8.904
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
CEO: Dr. Jill C. Milne, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...